SEC Form 10-Q Summary
Filing/entity note: The supplied filing is for Seneca Biopharma, Inc. (formerly Neuralstem, Inc.), not Palisade Bio, Inc. It covers the quarter and nine months ended September 30, 2020, and was filed November 10, 2020. The financial statements are unaudited and prepared under U.S. GAAP.
Business Context and Reporting Period
Seneca is a clinical-stage biopharmaceutical company developing neural stem-cell and small-molecule therapies. Management was winding down existing preclinical and clinical programs, pursuing out-licensing or sale of NSI-566 and NSI-189, and evaluating new assets for acquisition or in-licensing. The company reported seven full-time employees at September 30, 2020.
The company had not generated revenue from commercial product sales. Reported revenue consisted primarily of intellectual-property license fees and limited royalty revenue.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $2,500 in 2020 and 2019 | $11,020 in 2020 versus $12,894 in 2019 |
| Operating expenses | $2.35 million versus $2.13 million | $6.29 million versus $6.51 million |
| Operating loss | $2.34 million versus $2.12 million | $6.28 million versus $6.50 million |
| Net loss | $2.32 million versus $1.76 million | $11.85 million versus $6.31 million |
| Loss per share | $0.13 versus $0.59 | $0.93 versus $4.80 |
| R&D expense | $466,000, down 44% | $1.61 million, down 51% |
| G&A expense | $1.88 million, up 44% | $4.68 million, up 46% |
| Operating cash flow | Not separately provided | $(6.83) million versus $(5.21) million |
Revenue was immaterial relative to expenses; therefore, reported operating and net margins were deeply negative and not economically meaningful as conventional margin measures.
- Cash and liquidity: Balance-sheet cash and cash equivalents were $12.65 million at September 30, 2020, including approximately $100,000 classified within assets held for sale. The cash-flow statement reported ending cash of $12.75 million, reflecting the separate presentation of disposal-group cash.
- Financing: Nine-month financing cash inflows were $14.47 million, including $11.15 million from common-stock sales and $3.55 million from warrant exercises.
- Debt and liabilities: Current liabilities were $1.00 million; no short-term note payable remained outstanding at September 30, 2020. Warrant liabilities were $44,954. The company also reported lease liabilities associated with assets held for sale.
- Capital structure: Common shares outstanding totaled 17.30 million at September 30, 2020, compared with 3.87 million at December 31, 2019. Stockholders’ equity was $14.12 million, compared with $5.13 million at year-end 2019.
- Accumulated deficit: $233.82 million at September 30, 2020.
Material Changes Versus the Prior Comparable Period
- R&D spending declined materially as clinical and preclinical activities were wound down.
- G&A expense increased due primarily to an enhanced management structure, including two executive hires and additional consulting activity.
- Nine-month net loss increased by approximately $5.53 million, primarily because of a $5.62 million non-cash warrant-inducement expense recorded in 2020.
- Cash increased from $5.11 million at December 31, 2019 to approximately $12.65 million at September 30, 2020, primarily through equity issuance and warrant exercises.
- Common shares outstanding increased substantially because of warrant exercises and a May 2020 offering of 5.0 million common shares for approximately $4.4 million of net proceeds.
- Assets and liabilities related to the NSI-566 neural stem-cell program were classified as held for sale: $899,538 of assets and $325,812 of liabilities. No binding sale agreement had been executed.
Guidance, Outlook, Risks and Unusual Items
Management expected existing cash to fund the current operating plan for more than 12 months after filing, but stated that additional capital would be required to pursue acquisitions, in-licensing, out-licensing and ongoing operations. The company had no committed future funding and did not expect to become profitable in the next several years.
- Going concern: The filing states that recurring losses, negative cash flows and the need for additional financing create substantial doubt about the company’s ability to continue as a going concern. Failure to raise capital could require significant curtailment, cessation of operations or bankruptcy proceedings.
- NSI-566 sale: Management believed a sale was probable within one year and expected proceeds to exceed the net carrying value, but completion and final terms were uncertain.
- Nasdaq compliance: The company was below Nasdaq’s $1.00 minimum bid-price requirement and had until December 10, 2020, subject to possible extension, to regain compliance. Delisting could impair liquidity and future financing.
- COVID-19: Management could not yet determine the short-term impact but warned of possible delays, higher clinical-trial and vendor costs, and reduced access to capital over the medium and long term.
- Warrant inducement: The January 2020 warrant exercise generated approximately $6.7 million of net proceeds but resulted in a $5.62 million non-cash inducement expense and additional replacement warrants.
- Other risks: Key risks included clinical and regulatory failure, inability to complete licensing or acquisition transactions, intellectual-property challenges, dependence on limited personnel, dilution from future equity issuances and volatility in the common stock.
- Controls and legal matters: Management concluded disclosure controls were effective as of September 30, 2020. The filing reported no current legal proceedings.
Investor Verification Checklist
- Confirm that the filing corresponds to Seneca Biopharma rather than Palisade Bio, Inc.
- Verify actual unrestricted cash available for operations after excluding disposal-group cash and assets held for sale.
- Assess the sustainability of the stated cash runway against operating cash use of $6.83 million for the first nine months of 2020.
- Review the going-concern disclosure and the company’s ability to obtain additional equity, debt, licensing or asset-sale proceeds.
- Track the status and economics of the proposed NSI-566 sale, for which no binding agreement had been signed.
- Evaluate Nasdaq minimum-bid compliance and the potential effect of delisting on financing and liquidity.
- Analyze dilution from outstanding options, warrants, preferred-stock conversion rights and the company’s $100 million shelf registration statement.